FUSIONQUANT Trademark

Trademark Overview


On Wednesday, May 14, 2003, a trademark application was filed for FUSIONQUANT with the United States Patent and Trademark Office. The USPTO has given the FUSIONQUANT trademark a serial number of 78249512. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, October 9, 2015. This trademark is owned by IPSOGEN. The FUSIONQUANT trademark is filed in the Pharmaceutical Products category with the following description:

Diagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell...

General Information


Serial Number78249512
Word MarkFUSIONQUANT
Filing DateWednesday, May 14, 2003
Status710 - CANCELLED - SECTION 8
Status DateFriday, October 9, 2015
Registration Number2930568
Registration DateTuesday, March 8, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 14, 2004

Trademark Statements


Goods and ServicesDiagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma; pharmaceutical preparations for treatment of muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma
Pseudo MarkFUSION QUANT

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, October 9, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIPSOGEN
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Party NameIPSOGEN
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Party NameIPSOGEN
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Trademark Events


Event DateEvent Description
Friday, October 9, 2015CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Monday, March 21, 2011REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, March 18, 2011CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, March 3, 2011TEAS SECTION 8 & 15 RECEIVED
Tuesday, March 8, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, December 14, 2004PUBLISHED FOR OPPOSITION
Wednesday, November 24, 2004NOTICE OF PUBLICATION
Friday, October 8, 2004LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, October 6, 2004ASSIGNED TO LIE
Thursday, September 30, 2004APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 15, 2004AMENDMENT FROM APPLICANT ENTERED
Thursday, August 26, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2004Sec. 1(B) CLAIM DELETED
Thursday, August 26, 2004PAPER RECEIVED
Wednesday, June 23, 2004LETTER OF SUSPENSION E-MAILED
Friday, May 28, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 28, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 28, 2004PAPER RECEIVED
Thursday, December 11, 2003NON-FINAL ACTION MAILED
Thursday, December 4, 2003ASSIGNED TO EXAMINER
Wednesday, July 23, 2003PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, July 23, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 13, 2003CASE FILE IN TICRS
Wednesday, August 13, 2003CASE FILE IN TICRS
Wednesday, July 23, 2003PAPER RECEIVED